PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-month period ended

condensed Consolidated Financial Statements for the three and six-month period ended June 30, 2020, included herein, have been prepared in accordance with International Financial Reporting Standards

( IFRS ) as issued by the International Accounting Standards Board ( IASB ). The Consolidated Financial Statements are presented in euros. All references in this interim report to $, and U.S. dollars mean

U.S. dollars and all references to and euros mean euros, unless otherwise noted.

This interim report, including

Management s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the

Securities Act. All statements other than present and historical facts and conditions contained in this interim report, including statements regarding our future results of operations and financial position, business strategy, plans and our

objectives for future operations, are forward-looking statements. When used in this interim report, the words anticipate, believe, can, could, estimate, expect,

intend, is designed to, may, might, plan, potential, predict, objective, scheduled, should, will or the negative of

these and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those projected in any forward-looking statement. Factors that may cause actual results to differ from those in any

forward-looking statement include, without limitation: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; inconclusive clinical trial results or

clinical trials failing to achieve one or more endpoints, early data not being repeated in ongoing or future clinical trials, failures to secure required regulatory approvals, disruptions from failures by third-parties on whom we rely in connection

with our clinical trials, delays or negative determinations by regulatory authorities, changes or increases in oversight and regulation; increased competition; manufacturing delays or problems, inability to achieve enrollment targets, disagreements

with our collaboration partners or failures of collaboration partners to pursue product candidates, legal challenges, including product liability claims or intellectual property disputes, commercialization factors, including regulatory approval and

pricing determinations, disruptions to access to raw materials or starting material, proliferation and continuous evolution of new technologies; disruptions to Immatics business; management changes; dislocations in the capital markets; and

other important factors described under Risk Factors and Cautionary Note Regarding Forward-Looking Statements in our Registration Statement on Form F-1 filed with the Securities and

Exchange Commission on July 31, 2020 (the Registration Statement ) and under Risk Factors in this interim report. As a result of these factors, we cannot assure you that the forward-looking statements in this interim

report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these

statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a

result of new information, future events or otherwise, except as required by law.

, XPRESIDENT , ACTengine , ACTallo , ACTolog , XCEPTOR , TCER , AbsQuant , IMADetect and other trademarks or service marks of Immatics appearing in this interim report are the

property of the company. Solely for convenience, some of the trademarks, service marks, logos and trade names referred to in this interim report are presented without the and symbols, but such references are not intended to indicate, in

any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This interim report contains additional trademarks, service marks

and trade names of others. All trademarks, service marks and trade names appearing in this interim report are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies trademarks,

service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

this interim report, the terms Immatics, we, our, us, the Group and the Company refer to Immatics Biotechnologies GmbH and its subsidiaries, taken as a whole, unless the context

otherwise requires. The unaudited condensed consolidated financial statements and Management s Discussion & Analysis of Financial Condition and Results of Operations in this interim report are related to Immatics Biotechnologies GmbH

and its U.S. subsidiary Immatics U.S. Inc. Immatics N.V. was a shell company with no active trade or business or subsidiaries at June 30, 2020 and all relevant assets and liabilities as well as income and expenses were borne by Immatics

Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc.

Unaudited Condensed Consolidated Statement of Financial Position of Immatics Biotechnologies GmbH

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Loss of Immatics Biotechnologies GmbH

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Comprehensive Loss of Immatics Biotechnologies GmbH

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Cash Flows of Immatics Biotechnologies GmbH

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Changes in Shareholders Deficit of Immatics

Biotechnologies GmbH

The accompanying notes are an integral part of these condensed consolidated financial statements.

Notes to the Unaudited Condensed Consolidated Financial Statements of Immatics Biotechnologies GmbH

1. Group information

Immatics Biotechnologies

GmbH, together with its U.S. subsidiary, Immatics US Inc., ( Immatics or the Group ) is a biotechnology group that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of

cancer. Immatics Biotechnologies GmbH is located at Paul-Ehrlich Str. 15 in 72076 T bingen, Germany. Immatics Biotechnologies GmbH was founded in September 2000 as a German limited liability company. It is registered with the commercial

register at Stuttgart local court under HRB no. 382151. Immatics US, Inc. was founded in 2014 as a Delaware corporation.

The unaudited condensed

consolidated financial statements in this interim report are related to Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc.

N.V., a Dutch public limited liability company, was converted on July 1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH became a subsidiary of Immatics N.V. as part of the ARYA Merger on

July 1, 2020. The unaudited condensed consolidated financial statements are related to Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics U.S. Inc. Immatics N.V. was a shell company with no active trade or business or subsidiaries

at June 30, 2020 and all relevant assets and liabilities as well as income and expenses were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc.

These interim condensed consolidated financial statements of the Group for the three and six months ended June 30, 2020 were authorized for issue by the

Management Board of Immatics Biotechnologies GmbH on September 3, 2020.

2. Significant events and changes in the current reporting period

The Group was affected by the following events or transactions during the six months ended June 30, 2020.

On March 17, 2020, Immatics entered

into a definitive merger agreement with ARYA Sciences Acquisition Corp. ( ARYA ), a special purpose acquisition company sponsored by Perceptive Advisors. The transaction, which closed on July 1, 2020, was structured through Immatics

N.V., a Dutch public limited liability company. The merger ( ARYA Merger ) was effectuated in three principal steps:

December 2019, a novel strain of coronavirus ( COVID-19 ) emerged in Wuhan, China. While initially concentrated in China, spread of the outbreak is now worldwide. On January 30, 2020, the World

Health Organization declared the outbreak a pandemic and a global emergency. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures. The

extent of the pandemic and governmental responses may impact our ability to obtain raw materials and equipment used for research and development, obtain sufficient additional funds to finance our

operations, and conduct clinical trials, any of which could materially and adversely affect our business.

Management continues to monitor the situation

and enacted significant measures to protect the Group s supply chain, employees and the execution of clinical trials. To date, the pandemic has resulted in a slowdown in activities related to the Group s laboratory operations and at some

of its suppliers. The ongoing spread of COVID-19 may also negatively impact the Group s ability to conduct clinical trials, including potential delays and restrictions on the Group s ability to

recruit and retain patients, principal investigators and healthcare employees. COVID-19 could also affect the operations of contract research organizations, which may also result in delays or disruptions in

the supply of product candidates.

Due to COVID-19, the Group has also experienced delays in research activities

performed under its collaboration agreements. Consequently, the Group recognized less revenue under these agreements during the first two quarters of 2020 than previously planned. Management believes the declines in revenue associated with the delay

in research activities are largely temporary, as the revenue is primarily associated with non-refundable upfront payments recognized on a

cost-to-cost basis. COVID-19 may continue to impact the timing and amount of revenue recognized under these agreements in the

3. Significant accounting policies

The interim condensed consolidated financial statements of the Group as of June 30, 2020 and for the three and six months ended

June 30, 2020 and 2019 have been prepared in accordance with International Accounting Standard 34 ( Interim Financial Reporting ), as issued by the International Accounting Standards Board ( IASB ). The interim condensed

consolidated financial statements should be read in conjunction with the annual financial statements for the year ended December 31, 2019, which have been prepared in accordance with International Financial Reporting Standards

( IFRS ) as issued by the IASB, taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee ( IFRIC ).

The interim condensed consolidated financial statements are presented in Euros. Amounts are stated in thousands of Euros, unless otherwise indicated.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the

preparation of the Group s annual consolidated financial statements for the year ended December 31, 2019. The new and amended standards and interpretations applied for the first time as of January 1, 2020, as disclosed in the notes to

the consolidated financial statements for the year ended December 31, 2019, had no impact on the interim condensed consolidated financial statements of the Group for the three and six months ended as of June 30, 2020.

The Group has a non-controlling interest, representing approximately

3.96% of the Group s Immatics US, Inc. subsidiary as of June 30, 2020 and December 31, 2019. As part of the ARYA Merger, the non-controlling interest of MDACC in Immatics US, Inc. was exchanged

for ordinary shares in Immatics B.V.

4. Segment information

The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group s focus is on the

research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the

allocation of the Group s resources.

5. Other current assets

The Group recognizes receivables for government grants when it is reasonably assured that the grant will be received, and all

contractual conditions have been complied with. As of June 30, 2020, and December 31, 2019, no receivables were considered impaired.

expenses include 0.7 million fees paid for the successful arrangement of the Celgene Switzerland LLC ( BMS ) and Genmab A/S ( Genmab ) collaboration agreements as of June 30, 2020 and 0.6 million as of

As of June 30, 2020, the Group capitalized 1.6 million in costs associated with the ARYA Merger, which the Group

plans to deduct from the total proceeds of merger as a reduction in shareholder premium. These costs are directly attributed to the ARYA Merger and primarily related to legal and accounting fees.

Short-term deposits classified within other current assets have original maturity dates between three and nine months. During the six months ended

June 30, 2020, short term deposits decreased from 16.0 million to zero. The decrease resulted from a reallocation of the Group s funds from short-term deposits with maturity dates in excess of three months to money market funds.